SCM
VBIV

Segantii Capital Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Segantii Capital Management’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-467
Closed -$77K – 282
2017
Q1 		$77K Buy
+467
New +$63.2K 0.01% 229

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Segantii Capital Management's VBIV Position: Q2 2017 in Review

Segantii Capital Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2017, closing a stake of 467 shares — an estimated $77K sold.

Segantii Capital Management first reported a position in VBIV in Q1 2017 and held it in 1 quarter. The position peaked at $77K in Q1 2017. 37 funds tracked by Wall St. Rank hold VBIV as of Q2 2017.

  • Segantii Capital Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 467 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2017, an estimated $77K.
  • Segantii Capital Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $77K in Q1 2017.
  • 37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.